AU2022214391A1 - Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy - Google Patents

Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy Download PDF

Info

Publication number
AU2022214391A1
AU2022214391A1 AU2022214391A AU2022214391A AU2022214391A1 AU 2022214391 A1 AU2022214391 A1 AU 2022214391A1 AU 2022214391 A AU2022214391 A AU 2022214391A AU 2022214391 A AU2022214391 A AU 2022214391A AU 2022214391 A1 AU2022214391 A1 AU 2022214391A1
Authority
AU
Australia
Prior art keywords
ldh
polypeptide
amino acid
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022214391A
Other languages
English (en)
Other versions
AU2022214391A9 (en
Inventor
Raphaël FREDERICK
Maxime LIBERELLE
Pierre Sonveaux
Léopold THABAULT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Original Assignee
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL filed Critical Universite Catholique de Louvain UCL
Publication of AU2022214391A1 publication Critical patent/AU2022214391A1/en
Publication of AU2022214391A9 publication Critical patent/AU2022214391A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2022214391A 2021-02-01 2022-02-01 Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy Pending AU2022214391A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21154636.1 2021-02-01
EP21154636 2021-02-01
PCT/EP2022/052282 WO2022162233A2 (en) 2021-02-01 2022-02-01 Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy

Publications (2)

Publication Number Publication Date
AU2022214391A1 true AU2022214391A1 (en) 2023-08-10
AU2022214391A9 AU2022214391A9 (en) 2024-05-09

Family

ID=74494850

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022214391A Pending AU2022214391A1 (en) 2021-02-01 2022-02-01 Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy

Country Status (6)

Country Link
US (1) US20240116987A1 (https=)
EP (1) EP4284920A2 (https=)
JP (1) JP2024504467A (https=)
AU (1) AU2022214391A1 (https=)
CA (1) CA3206455A1 (https=)
WO (1) WO2022162233A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138822A1 (en) * 2019-05-02 2020-11-05 Universite Catholique De Louvain Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer
US12357256B2 (en) * 2023-06-23 2025-07-15 Smart Breast Corporation Computer assisted molecular imaging methods and systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6444425B1 (en) * 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US20050130263A1 (en) * 1999-10-29 2005-06-16 Genesis Research And Development Corp. Ltd. Compositions isolated from bovine mammary gland and methods for their use
RU2556800C2 (ru) 2010-06-14 2015-07-20 Ф.Хоффманн-Ля Рош Аг Пептиды, проникающие в клетки, и их применения
CA3138822A1 (en) * 2019-05-02 2020-11-05 Universite Catholique De Louvain Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer

Also Published As

Publication number Publication date
EP4284920A2 (en) 2023-12-06
JP2024504467A (ja) 2024-01-31
WO2022162233A2 (en) 2022-08-04
WO2022162233A3 (en) 2022-11-10
CA3206455A1 (en) 2022-08-04
US20240116987A1 (en) 2024-04-11
AU2022214391A9 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
Snyder et al. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids invivo
JP6249447B2 (ja) 癌治療用ペプチド剤
US10188699B2 (en) CAPCNA peptide therapeutics for cancer
US12528846B2 (en) BH4 stabilized peptides and uses thereof
US20240116987A1 (en) Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy
IL275774A (en) Variants of ATF5 peptide and their uses
US8445441B2 (en) Inhibitors of BCL-2
US9044421B2 (en) Treating MUC1-expressing cancers with combination therapies
WO2006095347A2 (en) VOLTAGE DEPENDENT ANION CHANNEL (VDACl) COMPOSITIONS AND METHODS OF USE THEREOF FOR REGULATING APOPTOSIS
Huang et al. Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr–Abl oncoprotein fused to the cytoplasmic transduction peptide
EP2004680B1 (en) N-terminal vdac variants and uses thereof
US20220289791A1 (en) Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer
US20110144034A1 (en) Inhibition of tumor metastases using protein kinase c (pkc) inhibitors
KR20230008296A (ko) 세포 투과성 pgk1 융합단백질을 포함하는 운동신경 질환 예방 또는 치료용 약학 조성물
US20160108100A1 (en) Interference Peptides and Use Thereof
IL194466A (en) Variants of the V-N terminal of VDAC and their use
EA042570B1 (ru) Способы и композиции для лечения рака

Legal Events

Date Code Title Description
SREP Specification republished